Bavarian Nordic A/S (BAVA.CO)
| Previous close | 151.90 |
| Open | 151.90 |
| Bid | 155.60 x 0 |
| Ask | 156.05 x 0 |
| Day's range | 151.90 - 158.05 |
| 52-week range | 125.55 - 222.00 |
| Volume | |
| Avg. volume | 541,667 |
| Market cap | 12.128B |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | 8.10 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
UPDATE 2-US CDC recommends routine use of Bavarian Nordic mpox vaccine for adults at risk
Danish pharmaceutical company Bavarian Nordic said on Wednesday a U.S. Centers for Disease Control and Prevention panel has voted in favor of recommending the routine use of Jynneos vaccine for adults at risk of mpox. The CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend that individuals 18 years and older with certain risk factors should receive two doses of Jynneos. The panel had previously recommended the vaccine for individuals at risk of mpox only during an outbreak, Bavarian said.
- Motley Fool
Why Emergent BioSolutions Stock Inched Slightly Higher Today
Emergent BioSolutions (NYSE: EBS) has been quite the up-and-down stock of late. On Monday, it had an up session on the market, creeping northward by 1.2% and exceeding the S&P 500's gain of 0.3%. The buyer is Denmark-headquartered peer Bavarian Nordic, which has handed over $270 million for the set of assets.
